Gilead Sciences is a leading biopharmaceutical company dedicated to developing and delivering innovative medicines for life-threatening diseases. Founded in 1987 and headquartered in Foster City, California, Gilead has built a strong reputation in antiviral research, particularly in HIV, hepatitis, and COVID-19 treatments. The company's portfolio includes groundbreaking therapies such as Truvada for HIV prevention, remdesivir (Veklury) for COVID-19, and a range of medications for liver diseases and oncology.

Beyond its pharmaceutical developments, Gilead is actively investing in cutting-edge research areas, including cell therapy, immuno-oncology, and AI-driven drug discovery. The company collaborates with biotech firms and research institutions to accelerate innovation, as seen in its recent partnership with Genesis Therapeutics. With a commitment to expanding global healthcare access, Gilead continues to play a vital role in advancing medical science and improving patient outcomes worldwide.